Duration of heart failure with preserved ejection fraction and treatment with sacubitril/valsartan: insights from the PARAGON-HF trial

Back

HFA Premium Access

Duration of heart failure with preserved ejection fraction and treatment with sacubitril/valsartan: insights from the PARAGON-HF trial

Session: Chronic heart failure - epidemiology, prognosis, outcome 2

Topic: Epidemiology, Prognosis, Outcome

Speaker: Doctor J. Ostrominski (Boston, US)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Doctor John Ostrominski

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

0 follower

6 more presentations in this session

Prognostic relevance of gradual weight changes on long-term mortality in chronic heart failure

Speaker: Doctor T. Taeger (Heidelberg, DE)

Access

Abstract

Slides

Long term outcomes after hospitalisation for acute heart failure

Speaker: Doctor J. Raby (High Wycombe, GB)

Access

Abstract

Slides

Prevalence and predictive factors of heart failure with improved ejection fraction (HFimpEF)

Speaker: Mr B. Solymossi (Budapest, HU)

Access

Abstract

Slides

The dynamic risk of heart failure: a systematic review and meta-regression of observational studies

Speaker: Doctor A. Shakoor (Rotterdam, NL)

Access

Abstract

Slides

Common strengths and challenges in heart failure care across the Belgian health care system: first results of the heart failure clinic of the future (HFCoF) project

Speaker: Doctor P. Timmermans (Hasselt, BE)

Access

Abstract

Slides

Access the full session

Chronic heart failure - epidemiology, prognosis, outcome 2

Speakers: Doctor J. Ostrominski, Doctor T. Taeger, Doctor J. Raby, Mr B. Solymossi, Doctor A. Shakoor...

Access

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources